SOUTH SAN FRANCISCO, Calif. – Feb. 03, 2004 – AGY Therapeutics, Inc. today announced the appointment of Timothy McBride as senior vice president of business development. In his new position Mr. McBride will be responsible for strategic partnering initiatives aimed at leveraging AGY’s expertise in target discovery and drug development in central nervous system indications.

“With a proven track record as an astute deal-maker and a deep understanding of industry collaborations, Tim will be a great asset to our team,” said Cynthia J. Ladd, AGY's president and CEO. “Tim’s in-depth experience in establishing key strategic partnerships will be important as we move forward with potential co-development and in-licensing opportunities aimed at advancing our lead product candidates more rapidly toward the clinic and harnessing the value of our imAGYne technology platform.”

Mr. McBride joins AGY from Acologix, Inc., a research and development-stage biotechnology company based in Emeryville Calif., where he served as chief business officer responsible for business development, as well as financial and operations management. Prior to Acologix, he was vice president of business development at Axys Pharmaceuticals, Inc., a pharmaceutical company engaged in small molecule drug discovery. At Axys Pharmaceuticals he led business development efforts, including initiating research collaborations, leading oncology compound in-licensing, managing in-line research relationships, and ultimately playing a significant role in Axys’ acquisition by Celera Genomics in November 2001.

Mr. McBride has more than 20 years of experience in pharmaceutical commercial management and business development. Before joining Axys he spent five years at Alza Corporation where he started Alza Pharmaceuticals’ sales force as director of sales and completed product in- and out-licensing as director of commercial development. He started his career at AstraZeneca Pharmaceuticals where he spent eleven years and held five commercial management positions. He holds a bachelor of arts degree from Bucknell University and a masters of business administration from Saint Mary’s College.

About AGY Therapeutics
AGY Therapeutics, a privately-held biotechnology company, is dedicated to discovering and developing novel treatments for central nervous system diseases, including stroke, depression, cognitive and mental diseases and brain tumors. With its proprietary imAGYne platform, the company has identified and characterized a vast number of promising drug targets and compounds to treat these diseases.

For additional information contact:
Kristin Nash
WeissCom Partners

About AGY l Research & Development l Investors & Partners l AGY News l Career Opportunities l Contact Us